Abstract: A method for bone regeneration which comprises administering a short term release composition into a bone area of a subject in need thereof, wherein the composition comprises a poly(lactic-co-glycolic acid) cross-linked alendronate (PLGA-ALN), wherein the composition releases the alendronate into the bone area, wherein the bone tissue of the bone area is exposed in situ to a therapeutically effective amount of the alendronate over 9 days.

Abstract: The present invention discloses a method of harnessing versatile phosphoramidation reactions to regioselectively link a group of alkynyl-/azido-containing compounds to post-synthetic nucleic acids primed with phosphate at the 5? termini. The method includes steps of: (a) monophosphoramidating H2N(CH2)nNH2 to the 5? end of the nucleic acid to form an intermediate 1 where n is an integer from 2 to 6, and the intermediate 1 has a formula of: (b) amidating the free —NH2 group of the intermediate 1 with to form an intermediate 2; and (c) reacting the terminal —N3 group of the intermediate 2 with 1-{3-{[4-(2-cyclooctyn-1-ylmethyl)benzoyl]amino}propyl}-4-{2-[4-(dimethylamino)phenyl]ethenyl}pyridinium hexafluorophosphate (Alkyne MegaStokes dye 608) by the SPAAC reaction to form modified nucleic acids. Without the presence of Cu(I), the modified nucleic acids were subjected to azide-alkyne cycloaddition in an aqueous solution to obtain various nucleic acid conjugates with a high yield.

Abstract: Bromodomain-containing protein 4 (BRI)) has recently emerged as an attractive epigenetic target for anticancer therapy. Iridium(III) complexes are useful as irreversible inhibitor of BRD4. Complex 1a of the formula: is particularly useful.

Abstract: The Toona sinensis extract of the present invention is prepared using supercritical fluid technique, wherein the method includes steps of: (a) drying the leaves of T. sinensis; (b) pulverizing the leaves as particles; and (c) extracting the particles with supercritical carbon dioxide to obtain the T. sinensis extract. This supercritical T. sinensis extract not only can decrease blood sugar level, but also promotes lipid degradation, inhibits the formation of huge lipid droplet and improves the metabolic symptoms. Accordingly, the T. sinensis extract further is able to be prepared as food supplement and pharmaceuticals.

Abstract: A method for evaluating the therapeutic efficacy of interferon (IFN)/ribavirin (RBV) for hepatitis C is disclosed. The method includes the steps of providing a specimen; mixing the specimen, a primer of a miRNA Let-7g and a poly-chain reaction (PCR) reagent together; and evaluating the efficacy of IFN/RBV on inhibiting a hepatitis C virus according to the expressing level of the miRNA Let-7g in the specimen detected by the PCR reagent.

Abstract: Disclosed are the isolation, purification and analysis of the triterpenoid compositions (including ergostane and lanostane) in the fruiting body of Antrodia cinnamomea using HPLC and NMR, as well as the stereo structures and the amounts of the triterpenoid compositions. The cytotoxicity of triterpenoids is also revealed. Based on the aforementioned techniques, the presence and amounts of ergostane and lanostane in the drugs, healthcare food or other goods are able to be detected.

Abstract: The present invention relates to a method for treating a bone loss disease, condition, or disorder in a subject in need thereof, comprising administering to said subject a pharmaceutically effective amount of a composition comprising thrombomodulin lectin-like domain (TMD1).

Abstract: The present disclosure provides a method for treating and/or preventing myopia, including: administering an RNA interference (RNAi) to a subject, wherein the RNA interference is capable of counteracting another RNA interference, and the other RNA interference is an RNA interference capable of inhibiting an expression of PAX-6 gene, and the RNA interference capable of inhibiting an expression of PAX-6 gene comprises microRNA-328.

Abstract: A compound of the formula: Also, a method for antagonizing STAT3 dimerization in a patient in need thereof which by administering to such patient a therapeutically acceptable dose of the compound of Formula I. Further, a method for treating a cancer patient in need thereof by administering a therapeutically effective dose of the compound of Formula I.

Abstract: The invention discloses a method of therapy of endothelial dysfunction, by administering microRNA let-7g to a subject in need, wherein the microRNA let-7g inhibits SMAD2 transcription factor from activation and translocation into nucleus, thereby decreasing monocyte cell adhesion, inflammation and thrombosis and increasing angiogenesis.

Abstract: Disclosed herein is a bi-specific antibody that specifically directs a therapeutic agent to a cancer cell by targeting a tumor antigen of the cancer cell, and thereby suppresses the growth of the cancer or blocking the invasion or metastasis of the cancer. The bi-specific antibody of the present disclosure includes a first antigen binding site that binds to polyethylene glycol (PEG); and a second antigen binding site that binds to a target ligand, such as a tumor antigen.

Abstract: A method for producing a silicon-containing zirconia calcined body includes wet mixing a mixture to obtain a mixed slurry, with the mixture including a silicon-containing zirconia powder, a sodium carbonate powder, a tetraethoxysilane, and an adhesive; drying the mixed slurry to obtain a caked mass; grinding and sieving the caked mass to obtain a mixed powder; pressurizing and shaping the mixed powder to obtain a blank; and calcining the blank in an environment at 900-1200° C. to obtain a silicon-containing zirconia calcined body. The silicon-containing zirconia calcined body can be sintered at 1415-1450° C. into a silicon-containing zirconia sintered body, with a shrinkage ratio during sintering the silicon-containing zirconia calcined body into the silicon-containing zirconia sintered body being 22-31%.

Abstract: The invention provides an oligonucleotide comprising a nucleotide sequence consisting of SEQ ID NO: 1. The invention also provides method for detecting target DNA in a sample with the oligonucleotide.

Abstract: The present invention is related to a method for detecting a protein comprising: (1) providing a fusion protein, wherein the fusion protein comprises the protein which is fused with a secondary antibody detected protein tag, wherein the secondary antibody detected protein tag comprises at least one epitope selected from the Fc region of at least one primary antibody which is capable of being detected by a corresponding secondary antibody; (2) contacting the fusion protein with a secondary antibody which binds to the secondary antibody detected protein tag to form a protein/antibody complex; and (3) detecting the protein/antibody complex.

Abstract: A compound of the formula: Also, a method for antagonizing STAT3 dimerization in a patient in need thereof which by administering to such patient a therapeutically acceptable dose of the compound of Formula I. Further, a method for treating a cancer patient in need thereof by administering a therapeutically effective dose of the compound of Formula I.

Abstract: The present invention provides a method for determining a survival rate and prognosis state for a patient having esophageal carcinoma, comprising: (a) providing a tissue sample from the patient; (b) measuring a expression level of a target gene in the tissue sample from the patient using reagents specific for the target gene product that are selected from the group consisting of probes, primers, antibodies, and antibody fragments, wherein the expression level is RNA expression, a protein expression at a cellular level or a tissue level; (c) comparing the expression level to a predetermined threshold indicative of a survival rate and prognosis state for the patient; and (d) providing a survival rate and prognosis state for the patient so that care for the patient is able to be determined in accordance with the survival rate and prognosis state, wherein the target gene is peptidase inhibitor 3 (PI3).

Abstract: A method of preparing an epitope for a secondary antibody detected protein tag, comprising: constructing a expressing vector, comprising a nucleotide sequence for encoding the secondary antibody detected protein tag comprising at least one epitope selected from at least one primary antibody which is detected by corresponding secondary antibody; expressing the vector in a host cell; and obtaining the secondary antibody detected protein tag which is expressed in the host cell. Further, a method for constructing a protein molecular weight marker ladder, comprising constructing a plurality of recombinant protein tags with different molecular weights, wherein each the recombinant protein tag comprises at least one epitope of primary antibody. Besides, a secondary antibody detected protein tag comprises at least two peptide sequences of epitopes selected from primary antibodies of at least two different species.

Abstract: A method for evaluating the therapeutic efficacy of interferon(IFN)/ribavirin(RBV) for hepatitis C is disclosed. The method includes the steps of providing a specimen; mixing the specimen, a primer of a miRNA Let-7g and a poly-chain reaction(PCR) reagent together; and evaluating the efficacy of IFN/RBV on inhibiting a hepatitis C virus according to the expressing level of the miRNA Let-7g in the specimen detected by the PCR reagent.

Abstract: A series of peptides with divergent confirmations including structures of formula (1A), (1B), (2) and (3) are provided. In the formula, wherein U, G, A, B, R1, R2 and T are as defined in the specification. The divergent peptides disclosed in the present invention are characterized in a mineral binding affinity function.

Abstract: A compound for treating a metabolic syndrome, comprising a structure of a 6Cs unit-3Cs unit-6Cs unit (C6-C3-C6) as shown in formula I, wherein: when R1 and R2 are both hydrogens, C3 has only single bonds; when R1 is an oxygen and R2 is one selected from a group consisting of an alkoxy, a benzyloxy and a halogen, C3 has only single bonds; when R1 is a deuterium and R2 is one selected from a group consisting of a hydrogen, an alkoxy, a benzyloxy and a halogen, C3 has one of a single bond and a double bond.